Kupando GmbH
Moritz Beissenhirtz is an experienced investment director specializing in life sciences, currently serving at Brandenburg Kapital GmbH since July 2023. Concurrently, Moritz is a member of the advisory board for Kupando GmbH, a German biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Previous roles include project manager in business development at Sartorius, and participation in new business development at Thermo Fisher Scientific. Moritz has extensive experience from Mologen AG in business development and IP management, alongside roles as a senior patent analyst at IP Bewertungs AG and postdoctoral positions at The Hebrew University of Jerusalem and the University of Potsdam. Moritz holds a Ph.D. in Biochemistry from the University of Potsdam and has completed lab work at the Università degli Studi di Firenze and The Hong Kong University of Science and Technology.
This person is not in the org chart
This person is not in any teams
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.